CD19×CD3 Bispecific Antibody Bridging ELISA Kit

Name: CD19×CD3 Bispecific Antibody Bridging ELISA Kit
SKU: DEIA-NS2696
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, cell culture supernates

Species Reactivity

Human

Detection Method

Bispecific Bridging ELISA

Intended Use

CD19×CD3 Bispecific Antibody Bridging ELISA Kit is developed for the detection of anti-CD19 & CD3 antibodies in serum and cell culture supernates. It is intended for research use only (RUO).

Contents of Kit

No.	Components	Size	Storage Conditions
1	Pre-coated Human CD3E & CD3G Protein Microplate	1 plate	Unopened 2–8°C, Opened 2–8°C
2	Anti-CD3 & CD19 Antibody Standard	20 μg	Unopened 2–8°C, Opened –70°C
3	Biotin-Human CD19 Protein	20 μg	Unopened 2–8°C, Opened –70°C
4	Streptavidin-HRP	20 μg	Unopened 2–8°C, avoid light, Opened –70°C, avoid light
5	10× Washing Buffer	50 mL	Unopened 2–8°C, Opened 2–8°C
6	2× Dilution Buffer	50 mL	Unopened 2–8°C, Opened 2–8°C
7	Substrate Solution	12 mL	Unopened 2–8°C, avoid light, Opened 2–8°C, avoid light
8	Stop Solution	7 mL	Unopened 2–8°C, Opened 2–8°C

Storage

1. Store the unopened kit at 2-8°C upon receipt
2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.
3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.

General Description

Bispecific antibodies (BsAbs) are engineered immunoglobulins that simultaneously bind two distinct antigens or two different epitopes on the same antigen. Their function depends on precise heavy- and light-chain pairing and molecular architecture, which determine avidity, orientation, and functional potency. By physically bridging immune effector cells to target cells, BsAbs can redirect and amplify immune-mediated cytotoxicity, offering enhanced tumor killing and a reduced likelihood of resistance compared with some monospecific therapies B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2. CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3s chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR. CD3-zeta, and the other CD3 molecules together constitute the TCR complex. A CD19 & CD3 bridging ELISA evaluates a bispecific molecule's ability to form the ternary complex between CD19 and CD3, providing a direct measure of the antibody's primary mechanism ofaction

Citations